BioLineRx (NASDAQ:BLRX) Share Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened

BioLineRx Ltd. (NASDAQ:BLRX) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.78 and traded as high as $3.86. BioLineRx shares last traded at $3.84, with a volume of 26,979 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BLRX shares. Jones Trading upgraded shares of BioLineRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 30th. Wall Street Zen raised BioLineRx to a “sell” rating in a report on Saturday, July 12th. Finally, HC Wainwright reiterated a “buy” rating on shares of BioLineRx in a research report on Tuesday, June 17th. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to MarketBeat, BioLineRx has a consensus rating of “Strong Buy” and an average price target of $26.00.

BioLineRx Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.87 and a current ratio of 2.06. The firm has a market capitalization of $16.37 million, a P/E ratio of -0.44 and a beta of 1.26. The company has a 50-day moving average price of $3.86 and a 200-day moving average price of $3.78.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.65). BioLineRx had a negative net margin of 45.34% and a negative return on equity of 49.74%. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.66 million. On average, sell-side analysts predict that BioLineRx Ltd. will post -5.8 earnings per share for the current year.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.